The Spanish government’s Princess of Asturias Awards, widely regarded as the country’s highest scientific honor, were presented Wednesday to three researchers whose work revolutionized DNA sequencing technology at a pivotal moment in the global fight against COVID-19. British chemists David Klenerman and Shankar Balasubramanian, alongside French biophysicist Pascal Mayer, received the prize for their contributions to next-generation sequencing methods that accelerated genomic surveillance and vaccine development during the pandemic.
The announcement came at the ninth annual ceremony in Oviedo, where the awards—endowed with a €50,000 prize for each laureate—are presented by the Princess of Asturias Foundation. While the award recognizes decades of foundational research, its timing underscores the enduring impact of their innovations amid ongoing debates over genomic surveillance and public health preparedness.
Klenerman, a professor at the University of Cambridge, and Balasubramanian, a former Cambridge colleague now at the University of Oxford, co-developed the Solexa sequencing technology in the early 2000s—a breakthrough that enabled rapid, high-throughput DNA analysis. Their work laid the groundwork for Illumina, the dominant player in global sequencing markets, whose platforms were later adapted for large-scale COVID-19 genome tracking. Mayer, a researcher at the French National Centre for Scientific Research (CNRS), expanded on these methods to improve single-molecule sequencing, a technique critical for detecting viral mutations in real time.
The award committee highlighted how their technologies allowed scientists to sequence entire viral genomes within days, a process that would have taken months with earlier methods. During the pandemic, this capability was deployed in projects like the COVID-19 Genomics UK (COG-UK) Consortium, where Balasubramanian’s team played a key role in mapping SARS-CoV-2 variants, including the Alpha variant first identified in Kent, England. Klenerman’s lab contributed to similar efforts in Cambridge, while Mayer’s group in France collaborated on European Union-funded sequencing initiatives.
Yet the recognition also arrives as genomic surveillance faces renewed scrutiny. In Spain, where the awards were conferred, debates persist over the ethical and logistical challenges of large-scale sequencing programs. A 2023 report by the Spanish Society of Epidemiology noted that while sequencing capacity improved during the pandemic, sustained funding for such infrastructure remains uncertain. Meanwhile, in the UK, where two of the laureates are based, health authorities have recently scaled back some genomic monitoring programs amid budget constraints, raising questions about the long-term viability of the technologies the award celebrates.
The Princess of Asturias Foundation, in its citation, emphasized that the laureates’ work “demonstrated the power of interdisciplinary science in addressing global crises.” Their methods, the statement added, had applications beyond infectious diseases, including cancer research and forensic science. However, the award does not address ongoing controversies over data privacy in genomic databases—a topic that has gained prominence in Europe following the EU’s General Data Protection Regulation (GDPR) and recent high-profile breaches in genomic research.
For now, the focus remains on the technical achievements. Klenerman and Balasubramanian’s early patents on sequencing-by-synthesis were licensed to Illumina, which became the backbone of genomic research during the pandemic. Mayer’s contributions, meanwhile, were instrumental in developing Oxford Nanopore Technologies’ portable sequencing devices, used in field hospitals and remote regions. The award ceremony itself was attended by Spanish Minister of Science and Innovation Diana Morant, who praised the laureates’ work as “a testament to how basic research can save lives.”
No immediate next steps were announced by the laureates or their institutions, though the Princess of Asturias Foundation has stated that the award includes a commitment to public lectures and outreach programs. The ceremony concluded with a call for continued investment in genomic infrastructure, a message that will resonate in capitals where public health budgets are under pressure.
